In a widely cited in-vivo model of atopic dermatitis, Turn Therapeutics’ atopic dermatitis candidate showed a dramatic reduction in disease severity versus placebo.
People with atopic dermatitis are in dramatic need of safe and effective non-steroid, non-injectable treatment options. Turn Therapeutics’ atopic dermatitis candidate showed a dramatic reduction in disease severity versus placebo.
At the conclusion of a seven-day disease induction, the mean severity score across all groups was 3.3 on the ISGA scale, an atopic dermatitis disease assessment that ranges from 0, or completely clear, to 4, or severe eczema.
After seven days of treatment, Turn Therapeutics’ candidate reduced ISGA score to 1.44, a 57% reduction, versus 3.0 for placebo, or a 10% reduction. The formula underlying Turn Therapeutics’ candidate has a history of safe use in humans and a confirmed lack of cytotoxicity or sensitization in existing clearances from the U.S. Food and Drug Administration.
“People with atopic dermatitis are in dramatic need of safe and effective non-steroid, non-injectable treatment options,” said Bradley Burnam, founder and CEO of Turn Therapeutics. “With a reduction of 1.89 points in the ISGA scale after only seven days, as well as confirmed inflammatory markers after induction, we expect to uncover notable immunological activity of our atopic dermatitis candidate.”
Study results and further information can be found on our Clinical Data page.
The statements contained herein may include prospects, statements of future expectations, and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance, or events may differ materially from those expressed or implied in such forward-looking statements.
